Comparative Pharmacology
Head-to-head clinical analysis: FENOFIBRIC ACID versus KYNAMRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENOFIBRIC ACID versus KYNAMRO.
FENOFIBRIC ACID vs KYNAMRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fenofibric acid is a peroxisome proliferator-activated receptor alpha (PPARα) agonist that increases lipolysis and clearance of triglyceride-rich lipoproteins and reduces apolipoprotein C-III production, leading to decreased triglycerides and increased HDL cholesterol.
Kynamro (mipomersen) is an antisense oligonucleotide that specifically binds to the mRNA of apolipoprotein B-100 (apoB-100), inhibiting its translation and reducing the production of apoB-100-containing lipoproteins, including LDL, VLDL, and Lp(a).
135 mg orally once daily
Kynamro (mipomersen) is administered subcutaneously at a dose of 200 mg once weekly.
None Documented
None Documented
Clinical Note
moderateFenofibric acid + Cyclosporine
"Fenofibric acid may increase the nephrotoxic activities of Cyclosporine."
Clinical Note
moderateFenofibric acid + Raltegravir
"Fenofibric acid may increase the myopathic rhabdomyolysis activities of Raltegravir."
Clinical Note
moderateFenofibric acid + Chenodeoxycholic acid
"The therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Fenofibric acid."
Clinical Note
moderateFenofibric acid + Ursodeoxycholic acid
Terminal elimination half-life is approximately 20 hours (range 15-25 h) for fenofibric acid, supporting once-daily dosing. In renal impairment, half-life may be prolonged.
Terminal elimination half-life is approximately 28-31 days (range 21-40 days) in patients with homozygous familial hypercholesterolemia, supporting weekly subcutaneous dosing.
Primarily renal as unchanged drug and glucuronide conjugate (approximately 60-70% of dose); remainder eliminated via biliary/fecal routes (~25%).
Primarily hepatobiliary elimination; less than 1% excreted unchanged in urine. Mipomersen is metabolized by endonucleases and exonucleases to shorter oligonucleotides, which are excreted in bile and feces.
Category C
Category C
Antilipemic
Antilipemic
"The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Fenofibric acid."